-
1.发明申请AUTOMATED SYSTEM FOR MEASUREMENT OF ZONE 1 IN ASSESSMENT OF SEVERITY OF RETINOPATHY OF PREMATURITY 审中-公开用于测量区域1的自动化系统评估临床前期严重程度公开(公告)号：US20160213242A1
公开(公告)日：2016-07-28
申请号：US14968622
申请日：2015-12-14
CPC分类号： A61B3/0025 , A61B3/0033 , A61B3/1241 , A61B5/0022
摘要： An automated method for diagnosing and evaluating severity of retinopathy of prematurity in a retina of a patient is provided that is superior to conventional techniques. A graphical user interface (GUI) is provided for receiving biographical information for the patient creating a patient record in a database via the GUI. A photograph of the retina of the patient is collected and placed in the patient record via the GUI. The photograph is then analyzed to determine vascular distributions within the retina. A zone 1 boundary is assigned to the retina based on a set of threshold levels with respect to the determined vascular distributions. A system for performing the automated method is also provided.
摘要翻译： 提供了一种诊断和评估患者视网膜视网膜病变严重程度的自动化方法，其优于常规技术。 提供图形用户界面（GUI），用于接收通过GUI在数据库中创建患者记录的患者的传记信息。 收集患者视网膜的照片，并通过GUI放置在患者记录中。 然后分析照片以确定视网膜内的血管分布。 基于关于所确定的血管分布的一组阈值水平将区域1边界分配给视网膜。 还提供了一种用于执行自动化方法的系统。
-
2.发明授权公开(公告)号：US09622657B2
公开(公告)日：2017-04-18
申请号：US14968622
申请日：2015-12-14
CPC分类号： A61B3/0025 , A61B3/0033 , A61B3/1241 , A61B5/0022
摘要： An automated method for diagnosing and evaluating severity of retinopathy of prematurity in a retina of a patient is provided that is superior to conventional techniques. A graphical user interface (GUI) is provided for receiving biographical information for the patient creating a patient record in a database via the GUI. A photograph of the retina of the patient is collected and placed in the patient record via the GUI. The photograph is then analyzed to determine vascular distributions within the retina. A zone 1 boundary is assigned to the retina based on a set of threshold levels with respect to the determined vascular distributions. A system for performing the automated method is also provided.
-
3.发明申请NORRIN REGULATION OF CELLULAR PRODUCTION OF JUNCTION PROTEINS AND USE TO TREAT RETINAL VASCULATURE EDEMA 审中-公开细菌生产蛋白质的正常调节和用于治疗视网膜血管内皮细胞公开(公告)号：US20160355559A1
公开(公告)日：2016-12-08
申请号：US14733729
申请日：2015-06-08
IPC分类号： C07K14/47
CPC分类号： C07K14/4705 , A61K38/00 , A61K38/1709 , A61K38/1891 , A61P27/02 , C07K14/475 , C07K14/515
摘要： A method of tightening inter-cellular junctions in retinal or choroidal vessel cells includes exposing the retinal or choroidal vessel cells to norrin. Upon sufficient contact time, for norrin to selectively up-regulate gene expression of VE-cadherin or claudin-5 in the retinal or choroidal vessel cells, the inter-cellular junctions are tightened. The method is also suitable for treating retinal pigment epithelial cells in wet macular degeneration.
摘要翻译： 在视网膜或脉络膜血管细胞中紧固细胞间连接的方法包括将视网膜或脉络膜血管细胞暴露于norrin。 在足够的接触时间后，为了选择性地上调VE-钙粘蛋白或紧密连接蛋白-5在视网膜或脉络膜血管细胞中的基因表达，norrin可以收紧细胞间连接。 该方法也适用于治疗湿性黄斑变性中的视网膜色素上皮细胞。
-
4.发明申请NORRIN REGULATION OF JUNCTION PROTEINS AND THE USE THEREOF TO TREAT EPITHELIAL OR ENDOTHELIAL MEMBRANE LEAKAGE INDUCED EDEMA 审中-公开结缔组织蛋白质的调节及其对上皮内膜或内膜损伤引起的EDEMA的影响公开(公告)号：US20160354435A1
公开(公告)日：2016-12-08
申请号：US14733876
申请日：2015-06-08
IPC分类号： A61K38/17
CPC分类号： A61K38/1709 , A61K38/1891 , A61P1/00 , A61P7/10 , A61P9/10 , A61P29/00 , C07K14/515 , C07K14/75
摘要： A method of tightening inter-cellular junctions in endothelial or epithelial cells includes exposing the endothelial or epithelial cells cells to norrin. Upon sufficient contact time, for norrin to selectively up- regulate gene expression of Cadherin or claudin-5 in the endothelial or epithelial cells, the inter-cellular junctions are tightened.
摘要翻译： 内皮细胞或上皮细胞中细胞间连接的紧固方法包括将内皮细胞或上皮细胞细胞暴露于norrin。 在足够的接触时间后，为了使norrin选择性地上调内皮细胞或上皮细胞中钙粘蛋白或紧密连接蛋白-5的基因表达，细胞间连接被收紧。
-
公开(公告)号：US20160022769A1
公开(公告)日：2016-01-28
申请号：US14777237
申请日：2013-03-15
IPC分类号： A61K38/17 , C12N15/11 , A61K31/505
CPC分类号： A61K38/1709 , A61K31/505 , A61K31/506 , A61K38/17 , A61K45/06 , C12N15/11 , A61K2300/00
摘要： The invention provides methods, compositions, and kits featuring Wnt signaling enhancing compounds for use in preventing or treating retinal disease.
摘要翻译： 本发明提供了用于预防或治疗视网膜疾病的Wnt信号传导增强化合物的方法，组合物和试剂盒。
-
公开(公告)号：US20180024138A1
公开(公告)日：2018-01-25
申请号：US15656558
申请日：2017-07-21
IPC分类号： G01N33/68
CPC分类号： G01N33/689 , A61K38/1709 , G01N2800/368 , G01N2800/52
摘要： A method for determining the necessity of a pre-term birth treatment is provided based on obtaining a biological sample from a subject. The biological sample is analyzed for the presence of (P33S;P168S) Frizzled4 (Fzd4) gene variation. The subject or a fetus thereof is then treated for a proclivity to pre-term birth. The Fzd4 protein itself can also be analyzed for the (P33S;P168S) Fzd4 mutation.
-
公开(公告)号：US20100239499A1
公开(公告)日：2010-09-23
申请号：US12381777
申请日：2009-03-17
申请人： Kimberly Drenser
发明人： Kimberly Drenser
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/0048 , A61K9/0051 , A61K9/1647 , A61K9/50 , A61K38/1709
摘要： An inventive method for treatment or prevention of vascular diseases of the retina is provided. A Norrin compound is optionally administered to a subject either directly and/or as expressed by a cell. The presence of the compound is either protective of or therapeutic for a pathological condition of the retina. Preferred pathological conditions are those linked to the absence of or mutation of norrin protein and are preferably Norrie disease, FEVR, or macular degeneration.
摘要翻译： 提供了用于治疗或预防视网膜血管疾病的创新方法。 Norrin化合物任选地直接和/或由细胞表达给受试者。 化合物的存在是对视网膜的病理状况的保护或治疗。 优选的病理条件是与诺瑞林蛋白质不存在或突变相关的病理条件，优选为诺里病，FEVR或黄斑变性。
-
公开(公告)号：US20150352184A1
公开(公告)日：2015-12-10
申请号：US14834967
申请日：2015-08-25
申请人： Kimberly Drenser
发明人： Kimberly Drenser
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/0048 , A61K9/0051 , A61K9/1647 , A61K9/50 , A61K38/1709
摘要： An inventive method for treatment or prevention of vascular diseases of the retina is provided. A Norrin compound is optionally administered to a subject either directly and/or as expressed by a cell. The presence of the compound is either protective of or therapeutic for a pathological condition of the retina. Preferred pathological conditions are those linked to the absence of or mutation of norrin protein and are preferably Norrie disease, FEVR, or macular degeneration.
摘要翻译： 提供了用于治疗或预防视网膜血管疾病的创新方法。 Norrin化合物任选地直接和/或由细胞表达给受试者。 化合物的存在是对视网膜的病理状况的保护或治疗。 优选的病理条件是与诺瑞林蛋白质不存在或突变相关的病理条件，优选为诺里病，FEVR或黄斑变性。
-
9.发明授权Rod opsin mRNA-specific ribozyme compositions and methods for the treatment of retinal diseases 失效Rod视蛋白mRNA特异性核酶组合物和治疗视网膜疾病的方法公开(公告)号：US06225291B1
公开(公告)日：2001-05-01
申请号：US09063667
申请日：1998-04-21
IPC分类号： A61K317105
CPC分类号： C12N15/1136 , A01K2217/05 , A61K38/00 , C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/121 , C12N2310/122 , C12N2310/127 , C12N2799/025
摘要： The subject invention provides materials and methods for efficient, specific reduction or elimination of unwanted mRNA. These materials and methods can be used in therapies for retinal diseases. In one embodiment, ribozymes which degrade mutant mRNA are used to treat retinitis pigmentosa.
摘要翻译： 本发明提供用于有效，特异性还原或消除不需要的mRNA的材料和方法。 这些材料和方法可用于治疗视网膜疾病。 在一个实施方案中，使用降解突变型mRNA的核酶来治疗色素性视网膜炎。
-
公开(公告)号：US09114078B2
公开(公告)日：2015-08-25
申请号：US12381777
申请日：2009-03-17
申请人： Kimberly Drenser
发明人： Kimberly Drenser
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/0048 , A61K9/0051 , A61K9/1647 , A61K9/50 , A61K38/1709
摘要： An inventive method for treatment or prevention of vascular diseases of the retina is provided. A Norrin compound is optionally administered to a subject either directly and/or as expressed by a cell. The presence of the compound is either protective of or therapeutic for a pathological condition of the retina. Preferred pathological conditions are those linked to the absence of or mutation of norrin protein and are preferably Norrie disease, FEVR, or macular degeneration.
摘要翻译： 提供了用于治疗或预防视网膜血管疾病的创新方法。 Norrin化合物任选地直接和/或由细胞表达给受试者。 化合物的存在是对视网膜的病理状况的保护或治疗。 优选的病理条件是与诺瑞林蛋白质不存在或突变相关的病理条件，优选为诺里病，FEVR或黄斑变性。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.026 秒)
